The utility of systemic‐immune inflammation index for predicting the disease activation in patients with psoriasis

Objective To evaluate the utility of systemic‐immune inflammation index (SII) in the management of patients with psoriasis. Method This retrospective case‐control study was conducted on patients who were admitted to the dermatology outpatient clinic. Patients with psoriasis (n = 71) were compared with a age and gender‐matched control group (n = 70) with other non‐inflammatory dermatologic diseases. Study and control groups were compared in terms of clinical characteristics and SII values (neutrophil X platelet/lymphocyte). Afterwards, 50th percentile value (4.5) for psoriasis area severity index (PASI) was calculated for the study group. Two subgroups were formed according to PASI values: (1) PASI